Innovative Medicines Initiative - IMI2, fondi UE per medicina innovativa
Pubblicati gli elenchi aggiornati degli argomenti che saranno al centro dei bandi 2020 del partenariato pubblico-privato europeo per la medicina innovativa, Innovative Medicines Initiative 2.
> Proprieta' intellettuale - via libera a misure UE per settore farmaceutico
Il partenariato pubblico-privato (PPP) Innovative Medicines Initiative 2 (IMI 2) coinvolge l'UE e la Federazione europea delle associazioni e delle industrie farmaceutiche (European Federation of Pharmaceutical Industries and Associations, EFPIA) con l'obiettivo di migliorare i sistemi sanitari dell'Unione.
> Horizon 2020: partenariato UE per la ricerca sulle malattie rare
IMI 2, topic delle call 2020
Il Consiglio di Amministrazione IMI2 ha pubblicato le bozze aggiornate degli argomenti (topic) che potrebbero essere finanziati nel quadro delle call 2020.
Nel dettaglio, per il bando che aprirà il 21 gennaio 2020 sono al vaglio sette topic:
- Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in Psoriatic Arthritis
- Innovations to accelerate vaccine development and manufacture
- Real-world clinical implementation of liquid biopsy
- Tumour plasticity
- Proton versus photon therapy for oesophageal cancer – a trimodality strategy
- Handling of protein drug products and stability concerns
- Academia and industry united innovation and treatment for tuberculosis (UNITE4TB)
Una seconda call verrà pubblicata il 23 giugno 2020 e riguarderà altre tematiche:
Neurodegeneration and other neuroscience priorities
- Rare neurodegenerative and neurocognitive diseases clinical platform development
- Complement in neurodegenerative diseases
‘Pain’ portfolio
- Digital endpoints and placebo effect in chronic pain
Infection control including vaccines
- Development of innovative personalized diagnostics and patient-guided therapies for the management of sepsis-induced immune suppression
- Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
Big data, digital health, clinical trials and regulatory research
- Data lakes
- Personalised endpoints
- Returning clinical trial data to patients: The proactive return of clinically relevant information to study participants during and after a clinical trial
Oncology
- Microbiome
Translational safety
- Pharmacodynamic drug-drug interaction predictive testing by learning algorithms to enhance safety
- Digital vivarium
Facilitating rare disease therapies (including Advanced Therapy Medical Products) reaching patients in Europe
- Clinical outcomes assessments for rare diseases
- Defragmenting and shortening the path to rare disease diagnosis by using genetic screening and digital technologies
L'elenco dei topic è soggetto a modifiche e verrà aggiornato dal CdA.
> Horizon 2020 - fondi UE per la Notte europea dei ricercatori
